Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Forbedring af brugen af ​​supplerende bryst-MR-screening for kvinder med ekstremt tætte bryster

10. september 2026 opdateret af: Abramson Cancer Center at Penn Medicine

The goal of this study is to increase MRI utilization among women with extremely dense breasts. The main question it seeks to answer is whether nudging of the provider, patient, or both increases the uptake of MRI among this group, and whether this effect differs between Black and White women.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Women with dense breasts have 3-5-fold increased risk for breast cancer as women without dense breasts. Dense breast tissue can "mask" small tumors, leading to reduced mammography sensitivity. Recent randomized controlled trials demonstrate that supplemental breast MRI screening improves detection of small, invasive cancers that are not detected by mammography. In January 2022, a Pennsylvania law went into effect mandating insurance coverage of supplemental screening for women with extremely dense breasts. Currently only a small fraction of eligible women with extremely dense breasts are receiving supplemental breast MRI screening. Clinical pathways to identify patients who are eligible for insurance coverage of supplemental breast MRI screening and communicate this option to patients and providers are needed to ensure equitable access to supplemental screening. This study therefore proposes a stepped wedge cluster randomized clinical trial to determine whether electronic health record (EHR) and secure text message nudges increase utilization of supplemental breast MRI screening among eligible women with extremely dense breasts.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1358

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Pennsylvania
      • Bala-Cynwyd, Pennsylvania, Forenede Stater, 19004
        • University of Pennsylvania

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 74 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Patient participants:

Inclusion Criteria:

  • Women aged 40-74
  • Recent non-actionable mammogram of less than 6 months
  • Mammogram performed at Penn Center for Advanced Medicine, Penn Presbyterian Hospital, Pennsylvania Hospital, or Radnor
  • Valid mobile phone number

Exclusion Criteria:

  • Prior history of breast cancer
  • No breast MRI within the past 2 years
  • No prior actionable mammogram within 6 months
  • No recent or concurrent ultrasound

Provider participants:

Inclusion Criteria:

  • Provider needs to have ordered the initial screening mammogram
  • Employed by Penn Health System and access to Penn Chart

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Screening
  • Tildeling: Randomiseret
  • Interventionel model: Faktoriel opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Usual care (no nudge)

Usual standard of care, no nudging.

Eksperimentel: Provider nudge only

Nudge sent to provider through electronic health record (EHR).

Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts

Eksperimentel: Patient nudge only

Nudge sent to the patient through text messaging.

Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts

Eksperimentel: Patient and provider nudge

Nudge sent to both provider through EHR, and to patient through text messaging.

Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts

Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Patients for Whom Breast MRI Was Ordered and/or Scheduled
Tidsramme: 6 months

Whether a breast MRI is ordered and/or scheduled within 6 months of the mammogram date

6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Patients for Whom Breast MRI Was Ordered
Tidsramme: 6 months

Whether an MRI is ordered within 6 months of the mammogram date. Analyzed separately from scheduling.

6 months
Number of Patients Who Scheduled a Breast MRI
Tidsramme: 6 months

Whether an MRI is scheduled within 6 months of the mammogram date. Analyzed separately from ordering.

6 months
Number of Patients Who Completed a Breast MRI
Tidsramme: 6 months

Whether an MRI is completed within 6 months of the mammogram date

6 months
False-positive Rate
Tidsramme: 6 months

False-positive rate among those women who schedule and undergo MRI, defined as the number of patients who received a positive MRI result (i.e., BIRADS score of 4 or 5) but did not have a subsequent cancer diagnosis

6 months
Cancer Detection Rate
Tidsramme: 6 months

Cancer detection rate among those women who schedule and undergo MRI

6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Anne Marie McCarthy, PhD, University of Pennsylvania

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

4. oktober 2023

Primær færdiggørelse (Faktiske)

4. april 2025

Studieafslutning (Faktiske)

4. april 2025

Datoer for studieregistrering

Først indsendt

15. marts 2023

Først indsendt, der opfyldte QC-kriterier

15. marts 2023

Først opslået (Faktiske)

28. marts 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. september 2026

Sidst verificeret

1. august 2024

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • UPCC 03123
  • P50CA244690 (U.S. NIH-bevilling/kontrakt)
  • 852666 (Registry Identifier: University of Pennsylvania Institutional Review Board)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner